Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor”

1,002 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,002 results

Very early researchStudy completedNCT04130152
What this trial is testing

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 22
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Not applicableStudy completedNCT00897663
What this trial is testing

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

Who this might be right for
Brain and Central Nervous System Tumors
Alliance for Clinical Trials in Oncology 56
Not applicableStudy completedNCT05724589
What this trial is testing

The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.

Who this might be right for
Aging
Institute of Dermatology, Thailand 28
Testing effectiveness (Phase 2)Study completedNCT02321540
What this trial is testing

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 13
Testing effectiveness (Phase 2)UnknownNCT05548348
What this trial is testing

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Who this might be right for
Non-small Cell Lung CancerEGFR G719XEGFR L861Q+1 more
Chongqing University Cancer Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00020917
What this trial is testing

Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer

Who this might be right for
Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Not applicableStudy completedNCT00764140
What this trial is testing

Tumor Growth Factors in Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital 400
Testing effectiveness (Phase 2)Study completedNCT03219476
What this trial is testing

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
Medical College of Wisconsin 37
Testing effectiveness (Phase 2)Ended earlyNCT01928615
What this trial is testing

Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 2
Testing effectiveness (Phase 2)Looking for participantsNCT07180160
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Wenjin Yin 123
Testing effectiveness (Phase 2)Study completedNCT02646020
What this trial is testing

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 138
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Testing effectiveness (Phase 2)Looking for participantsNCT06156527
What this trial is testing

Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Who this might be right for
Lazertinib
National Cancer Center, Korea 120
Large-scale testing (Phase 3)Study completedNCT01964391
What this trial is testing

Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 174
Large-scale testing (Phase 3)Looking for participantsNCT03201861
What this trial is testing

Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

Who this might be right for
Tubular Breast CancerMucinous Breast CancerInvasive Duct Carcinoma of Breast
RenJi Hospital 762
Early research (Phase 1)Looking for participantsNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 48
Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Early research (Phase 1)Ended earlyNCT03082300
What this trial is testing

ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Global Development, Inc. 3
Load More Results